Literature DB >> 22965570

Inflammatory markers are associated with outcome in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization.

Megan E McNally1, Antonio Martinez, Hooman Khabiri, Gregory Guy, Anthony J Michaels, James Hanje, Robert Kirkpatrick, Mark Bloomston, Carl R Schmidt.   

Abstract

BACKGROUND: The serum neutrophil-lymphocyte ratio (NLR) is associated with outcomes in several solid organ cancers, including hepatocellular carcinoma (HCC).
METHODS: We reviewed our experience in patients with HCC who underwent transarterial chemoembolization (TACE) as the initial treatment. Serum complete blood counts were used to calculate the NLR before and after TACE. The Kaplan-Meier method was used to determine survival and significant differences between groups by the log-rank test.
RESULTS: There were 103 patients identified who underwent TACE for HCC. The median age was 60.5 years. Median overall survival was 12.6 (95% confidence interval 8.3-17) months. Median survival in patients with a high preprocedural NLR was 4.2 months compared to 15 months in those with a normal NLR (p = 0.021). In those whose NLR either rose 1 month after treatment or remained elevated, survival was worse compared to those who normalized or remained normal (18.6 vs. 10.6 months, p = 0.026). The same was true at 6 months (21.3 vs. 9.5 months, p = 0.002). An unresponsive NLR was associated with very poor outcome (median survival 3.7 months). Multivariate analysis of clinicopathologic factors showed that presence of extrahepatic disease and high NLR were independent factors associated with worse survival.
CONCLUSIONS: Our study demonstrates that periprocedural trends of serum NLR are associated with outcome in unresectable HCC undergoing TACE. Serum NLR is easy to calculate from a routine complete blood count with differential. Along with liver function, serum NLR may be helpful to clinicians in providing prognostic information and monitoring response to therapy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22965570     DOI: 10.1245/s10434-012-2639-1

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  28 in total

1.  The elevated preoperative neutrophil-to-lymphocyte ratio predicts poor prognosis in intrahepatic cholangiocarcinoma patients undergoing hepatectomy.

Authors:  Qing Chen; Liu-Xiao Yang; Xue-Dong Li; Dan Yin; Shi-Ming Shi; Er-Bao Chen; Lei Yu; Zheng-Jun Zhou; Shao-Lai Zhou; Ying-Hong Shi; Jia Fan; Jian Zhou; Zhi Dai
Journal:  Tumour Biol       Date:  2015-02-12

2.  Neutrophil-lymphocyte ratio as a predictor of outcomes for patients with hepatocellular carcinoma undergoing TAE combined with Sorafenib.

Authors:  Kai Wei; Meng Wang; Wei Zhang; Han Mu; Tian-Qiang Song
Journal:  Med Oncol       Date:  2014-05-04       Impact factor: 3.064

3.  Post-embolization syndrome as an early predictor of overall survival after transarterial chemoembolization for hepatocellular carcinoma.

Authors:  Meredith C Mason; Nader N Massarweh; Aitua Salami; Mark A Sultenfuss; Daniel A Anaya
Journal:  HPB (Oxford)       Date:  2015-09-16       Impact factor: 3.647

4.  Pre-treatment neutrophil-to-lymphocyte ratio affects survival in patients with advanced hepatocellular carcinoma treated with sorafenib.

Authors:  Leonardo Gomes da Fonseca; Romulado Barroso-Sousa; Afonso da Silva Alves Bento; Bruna Paccola Blanco; Gabriel Luis Valente; Tulio Eduardo Flesch Pfiffer; Paulo Marcelo Hoff; Jorge Sabbaga
Journal:  Med Oncol       Date:  2014-10-02       Impact factor: 3.064

Review 5.  Role of inflammatory markers as hepatocellular cancer selection tool in the setting of liver transplantation.

Authors:  Russell E Rosenblatt; Zaid H Tafesh; Karim J Halazun
Journal:  Transl Gastroenterol Hepatol       Date:  2017-11-21

6.  Elevated NLR in gallbladder cancer and cholangiocarcinoma - making bad cancers even worse: results from the US Extrahepatic Biliary Malignancy Consortium.

Authors:  Eliza W Beal; Lai Wei; Cecilia G Ethun; Sylvester M Black; Mary Dillhoff; Ahmed Salem; Sharon M Weber; Thuy Tran; George Poultsides; Andre Y Son; Ioannis Hatzaras; Linda Jin; Ryan C Fields; Stefan Buettner; Timothy M Pawlik; Charles Scoggins; Robert C G Martin; Chelsea A Isom; Kamron Idrees; Harveshp D Mogal; Perry Shen; Shishir K Maithel; Carl R Schmidt
Journal:  HPB (Oxford)       Date:  2016-09-24       Impact factor: 3.647

7.  Diabetes mellitus and the neutrophil to lymphocyte ratio predict overall survival in non-viral hepatocellular carcinoma treated with transarterial chemoembolization.

Authors:  Jiangguo Zhang; Fengyun Gong; Ling Li; Manzhi Zhao; Jianxin Song
Journal:  Oncol Lett       Date:  2014-02-20       Impact factor: 2.967

8.  Prognostic significance of the neutrophil-to-lymphocyte ratio in primary liver cancer: a meta-analysis.

Authors:  Tong-Chun Xue; Lan Zhang; Xiao-Yin Xie; Ning-Ling Ge; Li-Xin Li; Bo-Heng Zhang; Sheng-Long Ye; Zheng-Gang Ren
Journal:  PLoS One       Date:  2014-05-02       Impact factor: 3.240

9.  High Neutrophil-Lymphocyte Ratio and Delta Neutrophil-Lymphocyte Ratio Are Associated with Increased Mortality in Patients with Hepatocellular Cancer.

Authors:  Nicole E Rich; Aarthi Parvathaneni; Ahana Sen; Mobolaji Odewole; Ana Arroyo; Arjmand R Mufti; Thomas A Kerr; Lafaine Grant; Shannan R Tujios; Marlyn J Mayo; William M Lee; Ju Dong Yang; Takeshi Yokoo; Purva Gopal; Yujin Hoshida; Hao Zhu; Adam C Yopp; Jorge A Marrero; Amit G Singal
Journal:  Dig Dis Sci       Date:  2021-05-03       Impact factor: 3.487

Review 10.  Inflammation-based scores: a new method for patient-targeted strategies and improved perioperative outcome in cancer patients.

Authors:  Dario Bugada; Massimo Allegri; Patricia Lavand'homme; Marc De Kock; Guido Fanelli
Journal:  Biomed Res Int       Date:  2014-04-27       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.